Rani, which has created a process to convert injectable drugs into pills, has attracted capital from investors including AstraZeneca and Ping An, boosting its total funding to $70m.
US-based biotherapeutics company Rani Therapeutics raised an undisclosed sum on Wednesday in a round backed by pharmaceutical firm AstraZeneca and insurance provider Ping An that took its overall funding to $70m.
The corporates were joined by fellow new investor Virtus Inspire Ventures, a boutique venture capital firm with offices in China and Hong Kong. Ping An invested through its Ping An Ventures unit.
Pharmaceutical firms Novartis and KPC Pharmaceuticals; GV, the corporate venturing division of conglomerate Alphabet; healthcare crowdfunding platform…
